Tim Guilliams is the founder of Healx. Latest round: Series C. Backed by R42 Group, Atomico, Balderton. Based in Cambridge, UK.
Tim Guilliams is the co-founder and CEO of Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases. The company uses an AI-driven discovery platform, Healnet, to identify new treatments for rare diseases, including those related to nerve-related tumor disorders, autosomal dominant polycystic kidney disease, and neurodevelopmental disorders. Healx recently announced a $47 million Series C financing round.
Full founder directory · Investor directory · Company funding database · Fundraising library